Ultragenyx Reports Second Quarter 2018 Financial Results and Corporate Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/23/2026
- Wall St set to open lower as oil, bond yields tick up
- BTIG’s Krinsky warns 2000-like signals are mounting
- HSBC remains max bullish on stocks, tells investors to lean into tech
- Analyst explains why the midterm outcome is a “fundamental non-event”
- Oil holds near two-week lows while diesel cracks hit record
Ultragenyx Pharma (RARE) Posts Smaller-than-Expected Q2 Loss
August 2, 2018 5:06 PM EDTUltragenyx Pharma (NASDAQ: RARE) reported Q2 EPS of ($1.06), $1.03 better than the analyst estimate of ($2.09). Revenue for the quarter came in at $12.8 million versus the consensus estimate of $5.42 million.
For earnings history and earnings-related data on Ultragenyx Pharma (RARE) click here.
... More